22,000 pounds of Johnsonville Bratwurst recalled over possible plastic contamination
Johnsonville recalled more than 20,000 pounds of its cheddar-flavored bratwurst after customers reported finding plastic in the product.
The American sausage company notified the U.S. Department of Agriculture's Food Safety and Inspection Service that they received two complaints from customers reporting hard plastic material in their bratwurst.
Johnsonville then issued a voluntary recall Saturday for about 22,672 pounds of cheddar-flavored bratwurst, shipped to stores in Georgia, Indiana, Kansas, Kentucky, Michigan, Minnesota, Ohio, Tennessee, Virginia, and Wisconsin.
There have been no reports of injuries.
USA TODAY has reached out to Johnsonville for comment.
Here's what to know about the Johnsonville recall and how to remedy the situation.
Need a break? Play the USA TODAY Daily Crossword Puzzle.
The potentially contaminated cheddar-flavored bratwurst was made on Feb. 5, 2025 with an establishment number of "Est. 1647" on the front of the label.
"FSIS is concerned that some product may be in consumers' freezers. Consumers who have purchased these products are urged not to consume them," the agency said. "These products should be thrown away or returned to the place of purchase."
Anyone concerned about a potential injury related to the recall should contact a healthcare professional immediately.
Johnsonville's Brats Cheddar Bratwurst product information:
Product: 19-ounce sealed firm tray packages containing five pieces of Johnsonville Brats Cheddar Bratwurst.
Package code: B9FOD
Establishment number: Est. 1647
Consumers with questions about the current recall may contact Consumer Relations coordinator Amanda Fritsch by phone at 888-556-2728 or via email at anachtweyfritsch@johnsonville.com.
This article originally appeared on USA TODAY: Johnsonville Bratwurst recall: Over 22,000 pounds affected
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
23 minutes ago
- Newsweek
Avocado's New Health Benefit Revealed
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. In news that may have many a millennial lunging for a slice of toast, eating an avocado a day has been linked to better sleep and boosted heart health as a result. Analysis of the largest randomized controlled trial on avocado consumption to date found a link between eating the fruit daily and improved sleep duration, despite the study being designed really to explore the superfood's impact on general health. The study had been supported by the Avocado Nutrition Center and marks the first time avocado intake has been associated with better sleep. "Sleep is emerging as a key lifestyle factor in heart health, and this study invites us to consider how nutrition—and foods like avocado—can play a role in improving it," said paper author and nutritional sciences professor Kristina Petersen of Penn State University in a statement. "Cardiovascular health is influenced by many factors, and while no single food is a silver bullet, some—like avocados—offer a range of nutrients that support multiple aspects of heart health." A stock image of a plate containing avocado on brown bread. A stock image of a plate containing avocado on brown bread. Getty Images Lisa Moskovitz, a registered dietitian and CEO at The NY Nutrition Group, spoke with Newsweek about the findings, giving avocados her seal of approval too. "Avocados are a superfood offering an assortment of heart-healthy nutrients—from cholesterol-lowering monounsaturated fats and fiber to blood pressure-regulating potassium and magnesium," she said. "There is a lot going on in a relatively small package. "I always recommend this Mediterranean staple to my clients as part of a wholesome, healthy and disease-fighting balanced diet." The study involved 969 racially and ethnically diverse American adults, all with elevated waist circumferences—a cardiovascular risk factor that affects nearly 60 percent of U.S. adults. Participants were randomized into two groups: one group consumed one avocado per day while the other had fewer than two avocados per month. Both groups otherwise maintained their usual diets over a six-month period. Although sleep was not the intended focus of the trial, the team's analysis revealed that those in the daily avocado group self-reported longer sleep durations. This finding adds to the growing scientific consensus around the fruit's health-promoting potential. Crucially, it also connects avocado intake to one of the American Heart Association's Life's Essential 8™—a set of key health behaviors and clinical measures that promote optimal cardiovascular health. Alongside sleep, the Essential 8 includes diet quality, physical activity, nicotine exposure, body weight, blood pressure, blood lipids and blood glucose. While the study showed modest reductions in LDL cholesterol and total cholesterol levels, and an increase in overall diet quality measured by the Healthy Eating Index 2015, there were no significant effects on the other Essential 8 components. However, the researchers note that this avenue—avocados and sleep—is ripe for future exploration. Why Do Avocados Improve Sleep? Avocados contain several nutrients that may play a role in sleep regulation. One-third of a medium avocado delivers 13 milligrams of tryptophan, an amino acid precursor to melatonin, the hormone that helps regulate sleep-wake cycles. It also contains 45 micrograms of folate, essential for melatonin production, and 15 milligrams of magnesium, which contributes to muscle relaxation and, as a result, improves sleep quality. Then there is the fruit's signature nutrient profile: 3 grams of fiber—one-third of which is soluble fiber known to reduce cholesterol—and 5 grams of heart-healthy monounsaturated fats, which help lower LDL cholesterol levels and reduce the risk of stroke and heart disease. Do you have a tip on a science story that Newsweek should be covering? Do you have a question about heart health? Let us know via science@ Reference Damani, J. J., Kris‐Etherton, P. M., Lichtenstein, A. H., Matthan, N. R., Sabaté, J., Li, Z., Reboussin, D., & Petersen, K. S. (2025). Effect of Daily Avocado Intake on Cardiovascular Health Assessed by Life's Essential 8: An Ancillary Study of HAT, a Randomized Controlled Trial. Journal of the American Heart Association, 14(5).
Yahoo
2 hours ago
- Yahoo
BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion
BioNTech will acquire all shares of CureVac after the two sides reached an agreement in a deal valued around $1.25 billion. Each share of CureVac, a clinical-stage biotech company, will be exchanged for about $5.46 in BioNTech American depositary shares. Upon the deal's closing, CureVac shareholders are expected to own between 4% and 6% of the German developer of RNA vaccines and immunotherapies. ICE Raids Have Sent Latino Shoppers Into Hiding and Big Brands Are Hurting The Secret to Retaining the Best Employees: Ask Them These Four Questions Here's How Much Money the U.S. Is Earning From Tariffs, in Charts How Home Depot Became Ground Zero in Trump's Deportation Push Supply Chains Become New Battleground in the Global Trade War BioNTech Chief Executive Ugur Sahin said the plan is to bring complementary capabilities between the two companies together to develop transformative cancer treatments. CureVac's operating subsidiary will become a wholly owned subsidiary of BioNTech following the close of the transaction. As part of this plan, BioNTech will integrate CureVac's research and manufacturing site in Tübingen, Germany. The deal was unanimously approved by both companies' management and supervisory boards. It is expected to close in 2025. Shares of CureVac surged 29% to $5.25 in premarket trading. Write to Denny Jacob at Pulls Outlook as Sales Fall Bojangles Is Exploring a Sale While the Fried-Chicken Market Is Hot Why Bosses Should Give Feedback in the Morning The Audacious Reboot of America's Nuclear Energy Program Muted May Inflation Defies Tariff Fears Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Is Fidelity Select Portfolio Medical Technology and Devices (FSMEX) a Strong Mutual Fund Pick Right Now?
If you have been looking for Sector - Health funds, a place to start could be Fidelity Select Portfolio Medical Technology and Devices (FSMEX). FSMEX has a Zacks Mutual Fund Rank of 1 (Strong Buy), which is based on various forecasting factors like size, cost, and past performance. Zacks categorizes FSMEX as Sector - Health, a segment packed with options. Sector - Health mutual funds offer investors a focus on the healthcare industry, one of the largest sectors in the American economy. These funds can include everything from pharmaceutical companies to medical device manufacturers and for-profit hospitals. Fidelity is responsible for FSMEX, and the company is based out of Boston, MA. Fidelity Select Portfolio Medical Technology and Devices made its debut in April of 1998, and since then, FSMEX has accumulated about $4.48 billion in assets, per the most up-to-date date available. The fund is currently managed by Edward Yoon who has been in charge of the fund since May of 2007. Investors naturally seek funds with strong performance. This fund has delivered a 5-year annualized total return of 5.12%, and it sits in the middle third among its category peers. If you're interested in shorter time frames, do not dismiss looking at the fund's 3 -year annualized total return of 3.37%, which places it in the bottom third during this time-frame. It is important to note that the product's returns may not reflect all its expenses. Any fees not reflected would lower the returns. Total returns do not reflect the fund's [%] sale charge. If sales charges were included, total returns would have been lower. When looking at a fund's performance, it is also important to note the standard deviation of the returns. The lower the standard deviation, the less volatility the fund experiences. Over the past three years, FSMEX's standard deviation comes in at 18.22%, compared to the category average of 15.64%. Over the past 5 years, the standard deviation of the fund is 19.24% compared to the category average of 16.64%. This makes the fund more volatile than its peers over the past half-decade. Investors should note that the fund has a 5-year beta of 0.92, which means it is hypothetically less volatile than the market at large. Alpha is an additional metric to take into consideration, since it represents a portfolio's performance on a risk-adjusted basis relative to a benchmark, which in this case, is the S&P 500. With a negative alpha of -7.95, managers in this portfolio find it difficult to pick securities that generate better-than-benchmark returns. Costs are increasingly important for mutual fund investing, and particularly as competition heats up in this market. And all things being equal, a lower cost product will outperform its otherwise identical counterpart, so taking a closer look at these metrics is key for investors. In terms of fees, FSMEX is a no load fund. It has an expense ratio of 0.63% compared to the category average of 1.11%. Looking at the fund from a cost perspective, FSMEX is actually cheaper than its peers. While the minimum initial investment for the product is $0, investors should also note that there is no minimum for each subsequent investment. Fees charged by investment advisors have not been taken into considiration. Returns would be less if those were included. Overall, Fidelity Select Portfolio Medical Technology and Devices ( FSMEX ) has a high Zacks Mutual Fund rank, and in conjunction with its comparatively similar performance, average downside risk, and lower fees, Fidelity Select Portfolio Medical Technology and Devices ( FSMEX ) looks like a great potential choice for investors right now. Your research on the Sector - Health segment doesn't have to stop here. You can check out all the great mutual fund tools we have to offer by going to to see the additional features we offer as well for additional information. For analysis of the rest of your portfolio, make sure to visit for our full suite of tools which will help you investigate all of your stocks and funds in one place. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Get Your Free (FSMEX): Fund Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
